# Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation

> **NCT02044328** · PHASE2 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 79 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT02044328
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2018-01
- **Final completion:** 2021-10
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044328, "Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02044328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*